Search results for "HERA"

showing 10 items of 14928 documents

Altered Semmes–Weinstein monofilament test results are associated with oxidative stress markers in type 2 diabetic subjects

2017

Abstract Background Different lines of evidence suggest that oxidative stress (OS) is implicated in the pathogenesis of diabetic neuropathy. The Semmes–Weinstein monofilament (SWM) test is an efficient tool for evaluating diabetic polyneuropathy and diabetic foot. In this study, we analyzed the association between OS markers and altered SWM test results in type 2 diabetes (T2DM) patients. Methods Seventy T2DM patients were studied and 34 showed altered SWM results. The clinical and biochemical parameters were determined using standardized methods. Levels of oxidized glutathione (GSSG) and malondialdehyde (MDA) were measured in circulating mononuclear cells using high-performance liquid chro…

0301 basic medicineMalemedicine.medical_specialtyGlutathione systemDiabetic neuropathySemmes–Weinstein monofilament testlcsh:MedicineType 2 diabetesmedicine.disease_causeGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMalondialdehydeType 2 diabetes mellitusmedicinePeripheral polyneuropathyHumansAgedAnthropometryGlutathione Disulfidebusiness.industryResearchlcsh:RGeneral Medicinemedicine.diseaseMalondialdehydeDiabetic footHealthy VolunteersOxidative Stress030104 developmental biologyEndocrinologychemistryDiabetes Mellitus Type 2Glutathione disulfideFemaleHemoglobinbusinessPolyneuropathy030217 neurology & neurosurgeryOxidative stressBiomarkersJournal of Translational Medicine
researchProduct

Effects of exercise frequency and training volume on bone changes following a multi-component exercise intervention in middle aged and older men: Sec…

2021

Progressive resistance training (PRT) combined with weight-bearing impact exercise are recommended to optimize bone health, but the optimal frequency and dose of training remains uncertain. This study, which is a secondary analysis of an 18-month intervention in men aged 50–79 years, examined the association between exercise frequency and the volume of training with changes in DXA and QCT-derived femoral neck (FN) and lumbar spine (LS) bone outcomes, respectively. Men were allocated to either thrice-weekly PRT plus impact exercise training (n = 87) or a non-exercising (n = 85) group. Average weekly exercise frequency (ExFreq) and training volume per session [PRT volume (weight lifted, kg), …

0301 basic medicineMalemedicine.medical_specialtyHistologyweight-bearing exercisePhysiologyEndocrinology Diabetes and Metabolismluuntiheys030209 endocrinology & metabolismlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawBone DensitySecondary analysisMedicineHumansolder menExerciseFemoral neckAgeddose-responsekehonpainoharjoitteluLumbar VertebraeExercise interventionbusiness.industryFemur NeckResistance trainingResistance TrainingMiddle Agedkeski-ikäiset030104 developmental biologymedicine.anatomical_structurePhysical therapyLumbar spinemiehetvoimaharjoitteluresistance trainingbusinessbone mineral densityExercise frequencyikääntyneetVolume (compression)Bone
researchProduct

Functional Improvement after Photothrombotic Stroke in Rats Is Associated with Different Patterns of Dendritic Plasticity after G-CSF Treatment and G…

2016

We have previously shown that granulocyte-colony stimulating factor (G-CSF) treatment alone, or in combination with constraint movement therapy (CIMT) either sequentially or concomitantly, results in significantly improved sensorimotor recovery after photothrombotic stroke in rats in comparison to untreated control animals. CIMT alone did not result in any significant differences compared to the control group (Diederich et al., Stroke, 2012;43:185-192). Using a subset of rat brains from this former experiment the present study was designed to evaluate whether dendritic plasticity would parallel improved functional outcomes. Five treatment groups were analyzed (n = 6 each) (i) ischemic contr…

0301 basic medicineMalemedicine.medical_specialtyLightmedicine.medical_treatmentMovement10208 Institute of NeuropathologyIschemialcsh:Medicine610 Medicine & health1100 General Agricultural and Biological Sciences03 medical and health sciences0302 clinical medicine1300 General Biochemistry Genetics and Molecular BiologyInternal medicineNeuroplasticityGranulocyte Colony-Stimulating FactormedicineAnimalscardiovascular diseasesRats Wistarlcsh:ScienceSalineStrokePhysical Therapy Modalities1000 MultidisciplinaryMultidisciplinaryNeuronal Plasticitybusiness.industryPyramidal Cellslcsh:RDendritesRecovery of Functionmedicine.diseaseCombined Modality TherapyCortex (botany)SurgeryGranulocyte colony-stimulating factorConstraint-induced movement therapyStroke030104 developmental biologyEndocrinologyConcomitant570 Life sciences; biologylcsh:Qbusiness030217 neurology & neurosurgeryResearch ArticlePLoS ONE
researchProduct

Emergent Uric Acid Treatment is Synergistic with Mechanical Recanalization in Improving Stroke Outcomes in Male and Female Rats.

2018

Preclinical and clinical studies support a promising, albeit not definitive, neuroprotective effect of emergent uric acid (UA) administration in ischemic stroke. We assessed the effects of UA in an ischemic stroke model relevant to the current treatment paradigm of mechanical thrombectomy within the STAIR/RIGOR recommendations. A cohort of male and female Wistar rats was subjected to ischemic stroke with mechanical recanalization under physiological monitoring. The effects of transient middle cerebral artery occlusion (tMCAO) with adjunctive UA (IV, 16 mg/kg) or vehicle treatment were assessed at 24 h and 7 days. Outcomes included neurofunctional impairment, brain infarct (TTC staining, MRI…

0301 basic medicineMalemedicine.medical_specialtyMechanical ThrombolysisBrain damageNeuroprotectionBrain Ischemia03 medical and health sciencesCresyl violetchemistry.chemical_compoundRandom Allocation0302 clinical medicineuric acidInternal medicineEdemamedicineischemic strokeAnimalsRats WistarStrokebusiness.industryGeneral Neurosciencerat modeladjunctive treatmentBrainRecovery of Functionmedicine.diseaseCombined Modality TherapyUric AcidStrokeDisease Models Animal030104 developmental biologyNeuroprotective AgentschemistrythrombectomyAdjunctive treatmentIschemic strokeCardiologyUric acidneuroprotectionFemalemedicine.symptombusiness030217 neurology & neurosurgeryNeuroscience
researchProduct

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

2016

The differential diagnoses for metabolic liver diseases may be challenging in clinical settings, which represents a critical issue for disorders such as lysosomal acid lipase deficiency (LAL-D). LAL-D is caused by deficient activity of the LAL enzyme, resulting in the accumulation of cholesteryl esters and triglycerides throughout the body, predominately in the liver, spleen, gastrointestinal tract, and blood vessel walls. LAL-D is a progressive, multi-organ disease with early mortality and significant morbidity characterized by a combination of hepatic dysfunction and dyslipidemia. Evidence suggests LAL-D may be substantially underdiagnosed or misdiagnosed, which is critical given that dis…

0301 basic medicineMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismDiseaseLysosomal acid lipase deficiencyBiochemistryGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGeneticsmedicineLysosomal storage diseaseHumansChildMolecular BiologyTriglyceridesNiemann-Pick DiseasesGaucher Diseasebusiness.industryWolman DiseaseInfantEnzyme replacement therapySterol Esterasemedicine.diseaseClinical trial030104 developmental biologyEarly DiagnosisSebelipase alfaDisease Progression030211 gastroenterology & hepatologyFemaleCholesterol EstersDifferential diagnosisbusinessDyslipidemiaMolecular genetics and metabolism
researchProduct

Preferred Music Listening Intervention in Nursing Home Residents with Cognitive Impairment: A Randomized Intervention Study.

2019

Background The current trend in addressing symptoms of dementia comprises non-pharmacological strategies such as music interventions for the management and improvement of cognitive function, memory, agitation, depression, or anxiety. Objective To determine the impact of a preferred music listening group intervention upon the functional, cognitive, and emotional dimensions in nursing home residents. Methods A randomized intervention study was carried out. The study was conducted from June to August 2015, and involved a preferred music listening group intervention lasting 60 minutes, 5 days/week during 8 weeks. A total of 119 adults aged ≥65 years, with annual permanent residence in the nursi…

0301 basic medicineMalemedicine.medical_specialtyPsychological intervention03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineDementiaHomes for the AgedHumansCognitive DysfunctionMusic TherapyDepression (differential diagnoses)AgedAged 80 and overbusiness.industryGeneral NeuroscienceTinetti testCognitionPatient PreferenceGeneral Medicinemedicine.diseasehumanitiesNursing HomesPsychiatry and Mental healthClinical Psychology030104 developmental biologySpainPhysical therapyAuditory PerceptionAnxietyResidenceFemaleGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up StudiesJournal of Alzheimer's disease : JAD
researchProduct

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomis…

2020

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has shown encouraging clinical efficacy with acceptable safety and tolerability in a phase 1 trial. The aim of this study was to evaluate venetoclax plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods In this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with relapsed or refractory multiple myeloma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received one to three previous therapies were enrolled from …

0301 basic medicineMalemedicine.medical_specialtyTime FactorsPopulationNeutropeniaPlaceboDexamethasoneBortezomib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical endpointMedicineHumansProgression-free survivaleducationAgededucation.field_of_studySulfonamidesbusiness.industryVenetoclaxBortezomibMiddle Agedmedicine.diseaseBridged Bicyclo Compounds HeterocyclicProgression-Free SurvivalVenetoclax BCL-2 inhibitor multiple myeloma Venetoclax plus bortezomib and dexamethasone030104 developmental biologyOncologychemistryTolerability030220 oncology & carcinogenesisFemalebusinessMultiple MyelomaProteasome Inhibitorsmedicine.drug
researchProduct

Cyclophosphamide plus vincristine and prednisone in the treatment of severe pemphigus vulgaris refractory to conventional therapy

1992

Five patients with severe pemphigus vulgaris refractory to conventional therapy with azathioprine and corticosteroids were treated with cyclophosphamide, vincristine and prednisone. One patient was not evaluable, while the remaining four patients showed a complete response. Duration of response was in the range of 13-94 months. Toxicity was mainly represented by alopecia, myelosuppression and gastrointestinal side-effects such as nausea/vomiting. Although cyclophosphamide and vincristine may induce severe side-effects, this association may be useful in controlling severe disease resistant to previous conventional therapies.

0301 basic medicineMalemedicine.medical_specialtyVincristineCyclophosphamideAdolescentNausea030106 microbiologyAzathioprinemacromolecular substancesGastroenterology03 medical and health sciences0302 clinical medicineRefractoryPrednisoneInternal medicinemedicineHumansPharmacology (medical)CyclophosphamideAgedPharmacologybusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseInfectious DiseasesOncologyVincristine030220 oncology & carcinogenesisVomitingPrednisoneDrug Therapy CombinationFemalemedicine.symptombusinessPemphigusmedicine.drug
researchProduct

Circulating Irisin Levels in Children With GH Deficiency Before and After 1 Year of GH Treatment.

2018

Abstract Purpose To evaluate circulating irisin levels in children with GH deficiency (GHD) and any relation with clinical and metabolic parameters. Patients Fifty-four prepubertal children (mean age, 7.4 ± 0.8 years) with idiopathic GHD treated with GH for at least 12 months and 31 healthy short children as control subjects. Methods Body height, body mass index (BMI), waist circumference (WC), IGF-I, HbA1c, lipid profile, fasting and after–oral glucose tolerance test glucose and insulin, insulin sensitivity indices, and irisin levels were evaluated at baseline and after 12 months of GH replacement (GHR). Results At baseline, children with GHD, in addition to having lower growth velocity (P…

0301 basic medicineMalemedicine.medical_specialtyWaistHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical Biochemistry030209 endocrinology & metabolismGrowth hormone receptorBiochemistrySettore MED/13 - EndocrinologiaGrowth hormone deficiencyBody Mass Index03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicinemedicineHumansProspective StudiesInsulin-Like Growth Factor IChildGrowth DisordersGlucose tolerance testmedicine.diagnostic_testbusiness.industryInsulinBiochemistry (medical)medicine.diseaseFibronectins030104 developmental biologyEndocrinologyTreatment OutcomeGrowth HormoneFemaleWaist CircumferenceLipid profilebusinessBody mass indexThe Journal of clinical endocrinology and metabolism
researchProduct

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct